• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BIT

BIOTRON LIMITED - Corporate Spotlight

0.00% ! 0.3¢
Market Cap $3.981M  !
Healthcare Biotechnology
Add to My Watchlist

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.3¢ 		Change
0.000(0.00%) 		Mkt cap ! $3.981M
Open High Low Value Volume
0.2¢ 0.3¢ 0.2¢ $2.167K 823.5K

Buyers (Bids)

No. Vol. Price($)
40 32458951 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 15542935 18
View Market Depth
Last trade - 16.10pm 15/05/2025 (20 minute delay) ?
BIT (ASX) Chart

Top Stories

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals

With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks...
Record gold prices, overlooked acreage & a looming maiden JORC. How this stock could become a household name As the gold metal has cooled from the ~US$3,500/oz mark in recent weeks, the commodity's performance through CY2024, and year...
Metgasco (ASX:MEL) kicks off Entitlement Offer to accelerate gas production and cashflow Metgasco (ASX:MEL) is conducting a partially underwritten shareholder entitlement offer to raise up to $750,000 at 0.2 cents per share. This is a 33% discount to the current 0.3 cents share price, 1 new share for every 3.89 existing shares (Record Date: 14 May 2025).Managing Director Ken Aitken j...
Gold, niobium, helium and more: Which explorers found what on Thursday? It can be hard to keep an eye on all of the ASX explorers. Here's what caught eyes on Thursday when it comes to junior...
‘Spectacular results’: Odyssey Gold (ASX:ODY) prepares for Au production An airborne survey electromagnetic survey has identified @32’ new promising exploration targets within Odyssey Gold @s (ASX:ODY) Tuckanarra project.Tuckanarra, near Meekatharra in WA, has been of interest to miners over many decades @ there are four existing open pits there, along...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.